Literature DB >> 18635008

Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides.

N D Sonawane1, Dan Zhao, Olga Zegarra-Moran, Luis J V Galietta, A S Verkman.   

Abstract

Inhibitors of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel have potential application as antisecretory therapy in cholera. We synthesized mono- and divalent CFTR inhibitors consisting of a malonic acid hydrazide (MalH) coupled via a disulfonic stilbene linker to polyethylene glycols (PEGs; 0.2-100 kDa). IC50 values for CFTR inhibition were 10-15 microM for the monovalent MalH-PEGs, but substantially lower for divalent MalH-PEG-MalH compounds, decreasing from 1.5 to 0.3 microM with increasing PEG size and showing positive cooperativity. Whole-cell patch-clamp showed voltage-dependent CFTR block with inward rectification. Outside-out patch-clamp showed shortened single-channel openings, indicating CFTR pore block from the extracellular side. Luminally added MalH-PEG-MalH blocked by >90% cholera toxin-induced fluid secretion in mouse intestinal loops (IC50 approximately 10 pmol/loop), and greatly reduced mortality in a suckling mouse cholera model. These conjugates may provide safe, inexpensive antisecretory therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635008      PMCID: PMC3322358          DOI: 10.1016/j.chembiol.2008.05.015

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  45 in total

1.  Evidence that CFTR channels can regulate the open duration of other CFTR channels: cooperativity.

Authors:  M E Krouse; J J Wine
Journal:  J Membr Biol       Date:  2001-08-01       Impact factor: 1.843

2.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Probing an open CFTR pore with organic anion blockers.

Authors:  Zhen Zhou; Shenghui Hu; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2002-11       Impact factor: 4.086

Review 4.  Molecular pharmacology of the CFTR Cl- channel.

Authors:  T C Hwang; D N Sheppard
Journal:  Trends Pharmacol Sci       Date:  1999-11       Impact factor: 14.819

5.  Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity.

Authors:  S Wang; H Yue; R B Derin; W B Guggino; M Li
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

6.  Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation.

Authors:  Hiroshi Oi; Daisuke Matsuura; Masami Miyake; Masamiti Ueno; Izumi Takai; Takeshi Yamamoto; Masayoshi Kubo; Joel Moss; Masatoshi Noda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 7.  Electrolyte transport in the mammalian colon: mechanisms and implications for disease.

Authors:  Karl Kunzelmann; Marcus Mall
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

8.  Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists.

Authors:  L V Galietta; S Jayaraman; A S Verkman
Journal:  Am J Physiol Cell Physiol       Date:  2001-11       Impact factor: 4.249

9.  Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.

Authors:  Baoxue Yang; Nitin D Sonawane; Dan Zhao; Stefan Somlo; A S Verkman
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

Review 10.  Permeation through the CFTR chloride channel.

Authors:  N A McCarty
Journal:  J Exp Biol       Date:  2000-07       Impact factor: 3.312

View more
  20 in total

Review 1.  Chloride channel-targeted therapy for secretory diarrheas.

Authors:  Jay R Thiagarajah; A S Verkman
Journal:  Curr Opin Pharmacol       Date:  2013-08-27       Impact factor: 5.547

Review 2.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

3.  Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.

Authors:  Lukmanee Tradtrantip; N D Sonawane; Wan Namkung; A S Verkman
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

4.  Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 Inhibits CFTR Chloride Channel Gating by Competition with ATP.

Authors:  Yonjung Kim; Marc O Anderson; Jinhong Park; Min Goo Lee; Wan Namkung; A S Verkman
Journal:  Mol Pharmacol       Date:  2015-07-14       Impact factor: 4.436

Review 5.  CFTR pharmacology.

Authors:  Olga Zegarra-Moran; Luis J V Galietta
Journal:  Cell Mol Life Sci       Date:  2016-10-04       Impact factor: 9.261

6.  Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.

Authors:  Onur Cil; Puay-Wah Phuan; Anne Marie Gillespie; Sujin Lee; Lukmanee Tradtrantip; Jianyi Yin; Ming Tse; Nicholas C Zachos; Ruxian Lin; Mark Donowitz; Alan S Verkman
Journal:  FASEB J       Date:  2016-11-08       Impact factor: 5.191

7.  Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease.

Authors:  David S Snyder; Lukmanee Tradtrantip; Chenjuan Yao; Mark J Kurth; A S Verkman
Journal:  J Med Chem       Date:  2011-07-12       Impact factor: 7.446

Review 8.  Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.

Authors:  Weiqiang Zhang; Naoaki Fujii; Anjaparavanda P Naren
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

9.  Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis.

Authors:  N D Sonawane; A S Verkman
Journal:  Bioorg Med Chem       Date:  2008-07-23       Impact factor: 3.641

Review 10.  CFTR inhibitors.

Authors:  Alan S Verkman; David Synder; Lukmanee Tradtrantip; Jay R Thiagarajah; Marc O Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.